Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
2.050
+0.010 (0.49%)
At close: Dec 16, 2025, 4:00 PM EST
2.050
0.00 (0.00%)
After-hours: Dec 16, 2025, 4:04 PM EST
Lisata Therapeutics Revenue
In the year 2024, Lisata Therapeutics had annual revenue of $1.00M.
Revenue (ttm)
$1.00M
Revenue Growth
n/a
P/S Ratio
16.37
Revenue / Employee
$41,154
Employees
26
Market Cap
18.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 22.49M | 4.55M | 25.36% |
| Dec 31, 2014 | 17.94M | 3.27M | 22.30% |
| Dec 31, 2013 | 14.67M | 338.57K | 2.36% |
| Dec 31, 2012 | 14.33M | 4.28M | 42.58% |
| Dec 31, 2011 | 10.05M | -59.77M | -85.61% |
| Dec 31, 2010 | 69.82M | 58.26M | 503.72% |
| Dec 31, 2009 | 11.57M | 11.48M | 13,743.64% |
| Dec 31, 2008 | 83.54K | -148.12K | -63.94% |
| Dec 31, 2007 | 231.66K | 185.94K | 406.66% |
| Dec 31, 2006 | 45.72K | 10.46K | 29.67% |
| Dec 31, 2005 | 35.26K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
LSTA News
- 5 weeks ago - Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year' - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 - GlobeNewsWire
- 2 months ago - Lisata Therapeutics to Present at LD Micro Main Event XIX - Newsfile Corp
- 2 months ago - Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement - GlobeNewsWire
- 2 months ago - Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial - GlobeNewsWire